Clinical Trials
Ensuring that our research impacts patients with cancer and patients with autoimmune disease is a key part of our strategy in the Lechner Lab.
We have a number of ongoing clinical trials to facilitate our bench to bedside research.
.png)
IRB #21-000633
Mechanisms of Immune Checkpoint Inhibitor Cancer Therapy-Associated and Spontaneous Thyroid Autoimmune Disease
PI: Dr. Lechner USC Site PI: Dr. Trevor Angell
Sponsors: NIH and Aramont Charitable Foundation
This study examines the cause of thyroid disease, including thyroiditis and Hashimoto's.
​
Participation: The study involves collection of peripheral blood and a thyroid fine needle aspirate. Compensation is provided.
Eligibility: Adults with active thyroid disease, including immune checkpoint inhibitor thyroid disease, autoimmune thyroid disease (such as Hashimoto’s or thyroiditis). Controls are also needed, and can include individuals with benign thyroid nodules.
Sites: UCLA Health Westwood and Santa Monica, USC Keck Medical Center, USC-LAC General Hospital
IRB #20-000494
Immune Profiles Associated with Development of Immune Toxicities in Checkpoint Immunotherapy-Treated Cancer Patients
PI: Dr. Lechner USC Site PI: Dr. Trevor Angell
Sponsors: UCLA, NIH​​
​
This study evaluates immune changes that predict the development of autoimmune toxicities in patients receiving cancer immunotherapy.
​
Participation: The study involves collection of peripheral blood every 3 months for 1 year. Blood collection can be done in conjunction with Oncology visits.
Eligibility: Adults with cancer being treated with immune checkpoint inhibitor therapy.
Sites: UCLA Health Westwood and Santa Monica, USC Keck Medical Center, USC-LAC General Hospital
IRB #23-000015
Mechanisms of Spontaneous and Cancer Immunotherapy Associated Autoimmune Disease
PI: Dr. Lechner
Sponsors: UCLA, Doris Duke Charitable Fuundation
​​
This study examines the immune system changes that lead to the development of autoimmune diseases, specifically the role of T cells and myeloid cells, so that disease modifying therapies can be identified.
​
Participation: The study involves collection of peripheral blood.
Eligibility: Adults with autoimmune disease, such as type 1 diabetes mellitus, thyroid autoimmune disease, and immunotherapy-related autoimmune disease.
Controls without autoimmune disease are also eligible.
Sites: UCLA Health and University of Southern California Keck Medical Center
Interested in participating or contributing to our research?
For questions email: MLechner@mednet.ucla.edu